Pediatrix Medical Group Hits New 52-Week High of $22.38

Pediatrix Medical Group, Inc. has reached a significant milestone by hitting a new 52-week high of USD 22.38 on November 4, 2025. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated remarkable growth over the past year, with a staggering 210.27% increase compared to the S&P 500's 19.89% performance.
With a market capitalization of USD 1,476 million, Pediatrix Medical Group is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 8.00, indicating a potentially attractive valuation relative to its earnings. The company has also shown robust financial health, with a return on equity of 18.01% and a manageable debt-to-equity ratio of 0.33.

In addition to its impressive stock performance, Pediatrix Medical Group has reported strong operational metrics, including a record operating cash flow of USD 244.56 million. The stock's performance has been bolstered by high institutional holdings, reflecting confidence in its fundamentals. As it continues to navigate the competitive landscape, Pediatrix Medical Group's recent achievements highlight its position as a notable player in the market.